Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease
Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease
About this item
Full title
Author / Creator
Sandborn, William J , Gasink, Christopher , Gao, Long-Long , Blank, Marion A , Johanns, Jewel , Guzzo, Cynthia , Sands, Bruce E , Hanauer, Stephen B , Targan, Stephan , Rutgeerts, Paul , Ghosh, Subrata , de Villiers, Willem J.S , Panaccione, Remo , Greenberg, Gordon , Schreiber, Stefan , Lichtiger, Simon , Feagan, Brian G and CERTIFI Study Group
Publisher
Waltham, MA: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
Waltham, MA: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
In this randomized trial involving adults with Crohn's disease in whom anti–tumor necrosis factor therapy had failed, ustekinumab, an antibody against interleukin-12 and 23, was associated with increased response rates, as compared with placebo.
Crohn's disease is a chronic inflammatory bowel disease.
1
One third of patients do not have a...
Alternative Titles
Full title
Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease
Authors, Artists and Contributors
Author / Creator
Gasink, Christopher
Gao, Long-Long
Blank, Marion A
Johanns, Jewel
Guzzo, Cynthia
Sands, Bruce E
Hanauer, Stephen B
Targan, Stephan
Rutgeerts, Paul
Ghosh, Subrata
de Villiers, Willem J.S
Panaccione, Remo
Greenberg, Gordon
Schreiber, Stefan
Lichtiger, Simon
Feagan, Brian G
CERTIFI Study Group
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1113980852
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1113980852
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa1203572
